The Globe and Mail reports in its Tuesday, Nov. 18, edition that TD Cowen analyst Michael Tupholme continues to rate Atkinsreal Group "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Tupholme boosted his share target by a loonie to $125. Analysts on average target the shares at $115.92. Mr. Tupholme says in a note: "Q3/25 PS&PM EBITDA was above consensus, and Atkinsrealis Services backlog hit a new record. While management lowered its 2025 ESR segment organic revenue growth guidance, it expects growth to reaccelerate in Q4/25 and remains confident in its medium-term outlook. Nuclear momentum continues to build, and Atkinsrealis raised its 2025 nuclear revenue outlook (third time this year). Atkinsrealis remains our 'Top Pick.'" The Globe reported on Sept. 27, 2024, and Nov. 9, 2024, that Mr. Tupholme rated Atkinsrealis "buy." It was then worth $53.87 and $76.02. The Globe reported on Nov. 4, 2025, that Canaccord Genuity analyst Yuri Lynk had reaffirmed his "buy" recommendation for Atkinsrealis. The shares were then going for $97.88.